Evidence map›Paper›PMID 34546542›Full record

ArticleInternational journal of hematology2022

Ability of final PET/CT to predict response to first-line treatment in real patients with classical Hodgkin lymphoma.

Laura Galvez-Carvajal, Cristina Quero, María Casanova, Carola Díaz, Jose Reinaldo Chícharo, Manuel Espeso, Ángeles Medina, Inmaculada Ramos, Emilio Alba, Antonio Rueda

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Laura Galvez-CarvajalMedical Oncology Intercentre Unit, Regional and Virgen de La Victoria University Hospitals, IBIMA, Teatinos, s/n, C.P., 29010, Málaga, Spain.
Cristina QueroMedical Oncology Department, Costa del Sol Hospital, Málaga, Spain.
María CasanovaHaematology Department, Costa del Sol Hospital, Málaga, Spain.
Carola DíazHaematology Department, Regional University Hospital, Málaga, Spain.
Jose Reinaldo ChícharoMolecular Imaging Unit, CIMES, Málaga, Spain.
Manuel EspesoHaematology Department, Regional University Hospital, Málaga, Spain.
Ángeles MedinaHaematology Department, Costa del Sol Hospital, Málaga, Spain.
Inmaculada RamosMedical Oncology Intercentre Unit, Regional and Virgen de La Victoria University Hospitals, IBIMA, Teatinos, s/n, C.P., 29010, Málaga, Spain.
Emilio AlbaMedical Oncology Intercentre Unit, Regional and Virgen de La Victoria University Hospitals, IBIMA, Teatinos, s/n, C.P., 29010, Málaga, Spain.
Antonio RuedaMedical Oncology Intercentre Unit, Regional and Virgen de La Victoria University Hospitals, IBIMA, Teatinos, s/n, C.P., 29010, Málaga, Spain. antonio.rueda.dominguez@juntadeandalucia.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Up to 25% of patients with classical Hodgkin lymphoma (cHL) and a negative interim PET/CT will progress. Unfortunately, there are few published studies on the predictive value of PET/CT performed after finishing treatment. The objective of our study was to assess the role of the final PET/CT (fPET/CT) in predicting progression in a retrospective series of patients treated in the last 10 years with a homogeneous protocol (ABVD + / - radiotherapy). We reviewed a cohort of 227 patients with newly diagnosed cHL. fPET/CT was performed on 212 patients (93%). In patients with a positive fPET, progression-free survival at 60 months was 17% (94% if fPET was negative, p = 0.000). The positive and negative predictive values for the fPET were 76% and 94%, respectively (Fisher's exact test, p = 0.000). In the subgroup of patients with advanced-stage cHL, progression-free survival at 60 months was 91% with negative fPET and 0% with positive fPET (p = 0.000). However, fPET was negative in 19 of the 29 patients with a positive interim PET/CT (only 2 showed progression). In conclusion, fPET is a useful tool to predict treatment failure in patients with newly diagnosed cHL, especially advanced-stage disease.

Indexed as

RadiotherapyAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMiddle AgedNeoplasm StagingBleomycinDacarbazineDoxorubicinVinblastineHodgkin lymphomaPETPredictive value

Identifiers

PMID34546542

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.